Concepedia

Marina Konopleva

MK

32

Publications

1.2K

Citations

17

H-Index

1999

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Harvard University

Dana-Farber Cancer Institute

University of Helsinki

Albert Einstein College of Medicine

Marina Konopleva is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, immunology, and pharmacology.

Top concepts

Publications per year

1999–2024

32

Publications

32

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

G. Borthakur, Hagop M. Kantarjian, Farhad Ravandi et al. · Haematologica · 2010 · 203 citations · Full text

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis et al. · Haematologica · 2020 · 134 citations · Full text

, , +15

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Marina Konopleva, Peter F. Thall, Cecilia Arana Yi et al. · Haematologica · 2015 · 119 citations · Full text

, , +18

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Heikki Kuusanmäki, Olli Dufva, Markus Vähä‐Koskela et al. · Blood · 2022 · 112 citations · Full text

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, Hagop M. Kantarjian, Naval Daver et al. · Blood · 2017 · 73 citations

Rows per page

1–5 of 32